&w=3840&q=100)
Reliance Industries sells 8.5 mn shares of Asian Paints for ₹1,876 cr
Billionaire Mukesh Ambani-led Reliance Industries on Monday sold 85 lakh shares of Asian Paints for Rs 1,876 crore through an open market transaction.
The share sale came days after Reliance Industries offloaded 3.50 crore equity shares or 3.64 per cent stake in Mumbai-based Asian Paints on Thursday.
According to the block deal data on the National Stock Exchange (NSE), Reliance Industries through its affiliate Siddhant Commercials Pvt Ltd disposed of 85 lakh shares, representing a 0.88 per cent stake in Asian Paints.
The shares were sold at an average price of Rs 2,207 apiece, taking the transaction value to Rs 1,875.95 crore.
Meanwhile, ICICI Prudential Mutual Fund (MF) bought these shares at the same price. With the acquisition of shares, ICICI Prudential MF's holding in Asian Paints rose to 2.12 per cent from 1.24 per cent.
Shares of Asian Paints increased 1.21 per cent to close at Rs 2,241 apiece on the NSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
20 minutes ago
- Time of India
Man loses 19.90 lakh in online scam
T'puram: A 57-year-old Poojappura resident fell victim to an online scam, losing Rs 19.90 lakh to fraudsters posing as stock market experts. After searching online for profitable shares, he was contacted by individuals claiming to represent 'Institution Buyers', an alleged govt-approved agency. They lured him with promises of guaranteed returns and added him to a WhatsApp group which shared fake success stories. Over 20 days, the victim transferred funds in 10 transactions, only to realize he had been duped. The victim reported the incident to city cyber police, who launched a probe into the fraudulent scheme. TNN
Time of India
21 minutes ago
- Time of India
State govt to launch Space Park project on Thursday
T'puram: The foundation stone for Kerala's ambitious Common Facility Centre (CFC) and Research & Development Centre (RDC) as part of the Space Park project will be laid on Thursday. The event will be held at the Hyatt Regency, Thycaud, in the capital. Chief minister Pinarayi Vijayan will inaugurate the event. Organized by Kerala Spacepark (KSPACE), the event marks a significant step in boosting the state's aerospace and defence sectors. Spanning 15.06 acres in Pallippuram, the project is backed by Nabard and aims to provide shared facilities for testing, inspection and innovation. The two-day event will also feature exhibitions, startup pitching sessions and industry-academia interactions. Various sponsorship and exhibition opportunities are open to institutions and startups. Registration for delegates and students is now open. The tender for the Space Park was awarded to Ircon International Ltd, a Govt of India undertaking institution under the ministry of railways. The project was granted a Rs 241 crore loan from Nabard for the construction of the buildings and the campus. The tender was called by the Kerala State IT Infrastructure Ltd to construct two key buildings—the CFC and RDC. The estimated completion of the project is 30 months. The new facilities will be built on 3.5 acres of the 18.5 acres allotted by state govt at Technopark Phase IV in Pallipuram. Currently, the Space Park office operates from a rented building in Pattom. The R&D facility will feature startup incubators and other research amenities.
Time of India
23 minutes ago
- Time of India
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads ( Originally published on Jun 16, 2025 ) U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters."They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData.A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%."I think it's only accelerating," Gleason Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs."The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals.'WAKEUP CALL'By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say.U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week."We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time."Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry."It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
